• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重复低剂量激发试验分析

Analysis of repeated low-dose challenge studies.

作者信息

Nolen Tracy L, Hudgens Michael G, Senb Pranab K, Koch Gary G

机构信息

RTI International, The Research Triangle Park, NC, 27709, U.S.A.

出版信息

Stat Med. 2015 May 30;34(12):1981-92. doi: 10.1002/sim.6462. Epub 2015 Mar 9.

DOI:10.1002/sim.6462
PMID:25752266
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4420691/
Abstract

Preclinical evaluation of candidate human immunodeficiency virus (HIV) vaccines entails challenge studies whereby non-human primates such as macaques are vaccinated with either an active or control vaccine and then challenged (exposed) with a simian-version of HIV. Repeated low-dose challenge (RLC) studies in which each macaque is challenged multiple times (either until infection or some maximum number of challenges is reached) are becoming more common in an effort to mimic natural exposure to HIV in humans. Statistical methods typically employed for the testing for a vaccine effect in RLC studies include a modified version of Fisher's exact test as well as large sample approaches such as the usual log-rank test. Unfortunately, these methods are not guaranteed to provide a valid test for the effect of vaccination. On the other hand, valid tests for vaccine effect such as the exact log-rank test may not be easy to implement using software available to many researchers. This paper details which statistical approaches are appropriate for the analysis of RLC studies, and how to implement these methods easily in SAS or R.

摘要

候选人类免疫缺陷病毒(HIV)疫苗的临床前评估需要进行攻毒研究,即对猕猴等非人灵长类动物接种活性疫苗或对照疫苗,然后用猿猴版本的HIV进行攻毒(暴露)。重复低剂量攻毒(RLC)研究中,每只猕猴接受多次攻毒(要么直到感染,要么达到最大攻毒次数),这种研究正变得越来越普遍,旨在模拟人类自然接触HIV的情况。RLC研究中通常用于检验疫苗效果的统计方法包括费舍尔精确检验的修正版本以及大样本方法,如常用的对数秩检验。不幸的是,这些方法并不能保证为疫苗接种效果提供有效的检验。另一方面,像精确对数秩检验这样的有效疫苗效果检验,使用许多研究人员可用的软件可能不容易实现。本文详细介绍了哪些统计方法适用于RLC研究的分析,以及如何在SAS或R中轻松实现这些方法。

相似文献

1
Analysis of repeated low-dose challenge studies.重复低剂量激发试验分析
Stat Med. 2015 May 30;34(12):1981-92. doi: 10.1002/sim.6462. Epub 2015 Mar 9.
2
Surrogates of protection in repeated low-dose challenge experiments.重复低剂量激发实验中的保护替代指标。
Stat Med. 2015 May 10;34(10):1747-60. doi: 10.1002/sim.6436. Epub 2015 Jan 28.
3
Timing of retroviral infection influences anamnestic immune response in vaccinated primates.
Viral Immunol. 2005;18(4):689-94. doi: 10.1089/vim.2005.18.689.
4
AIDS vaccines show promise in primates.艾滋病疫苗在灵长类动物身上显示出前景。
Clin Infect Dis. 2001 Oct 1;33(7):i-ii.
5
Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination.慢性感染而非接种疫苗后,猿猴免疫缺陷病毒特异性CD8 T细胞上抑制性受体程序性死亡1的表达水平升高。
J Virol. 2007 Jun;81(11):5819-28. doi: 10.1128/JVI.00024-07. Epub 2007 Mar 21.
6
Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV.在几个时间点对小群体中疫苗对病毒载量和免疫反应的相对治疗效果进行评估:黏膜和皮下多肽疫苗对感染猴免疫缺陷病毒(SHIV)的恒河猴的疗效
J Clin Virol. 2004 Dec;31 Suppl 1:S69-82. doi: 10.1016/j.jcv.2004.09.006.
7
Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.猕猴经鼻内接种灭活的捕获SHIV纳米球诱导HIV特异性抗体反应并预防阴道SHIV传播。
J Med Virol. 2004 Jul;73(3):368-77. doi: 10.1002/jmv.20100.
8
A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.一种可保护猕猴免受艾滋病侵害的非感染性猿猴/人类免疫缺陷病毒DNA疫苗。
J Virol. 2005 Mar;79(6):3419-28. doi: 10.1128/JVI.79.6.3419-3428.2005.
9
Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.疫苗诱导的猿猴免疫缺陷病毒特异性CD8 + T细胞可减少病毒复制,但不能预防猿猴免疫缺陷病毒疾病的进展。
J Immunol. 2009 Jul 1;183(1):706-17. doi: 10.4049/jimmunol.0803746.
10
Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges.一种含多聚体HIV gp160的多基因蛋白疫苗针对异源SHIV C亚型攻击的效力
AIDS. 2007 Sep 12;21(14):1841-8. doi: 10.1097/QAD.0b013e32828684ea.

引用本文的文献

1
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.探索临床前和临床环境中的 HIV 疫苗进展:从历史到未来展望。
Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368.
2
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.佐剂化 HIV-1 疫苗可促进抗体依赖的吞噬作用反应,并预防异源 SHIV 挑战。
PLoS Pathog. 2020 Sep 3;16(9):e1008764. doi: 10.1371/journal.ppat.1008764. eCollection 2020 Sep.
3
Estimating the basic reproduction number of a pathogen in a single host when only a single founder successfully infects.在仅有单个启动者成功感染的情况下,估计单宿主中病原体的基本繁殖数。
PLoS One. 2020 Jan 10;15(1):e0227127. doi: 10.1371/journal.pone.0227127. eCollection 2020.
4
An accurate approximation for the expected site frequency spectrum in a Galton-Watson process under an infinite sites mutation model.在无限位点突变模型下,高尔顿 - 沃森过程中预期位点频率谱的精确近似。
Theor Popul Biol. 2019 Jun;127:7-15. doi: 10.1016/j.tpb.2019.03.001. Epub 2019 Mar 12.
5
Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques.母体接种HIV-1包膜疫苗以获得全身和母乳免疫力,预防幼猴经口感染猿猴-人免疫缺陷病毒。
mSphere. 2018 Jan 10;3(1). doi: 10.1128/mSphere.00505-17. eCollection 2018 Jan-Feb.
6
Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.黏膜接种靶向 SIV 辅助抗原的异源病毒载体疫苗强烈抑制早期病毒复制。
EBioMedicine. 2017 Apr;18:204-215. doi: 10.1016/j.ebiom.2017.03.003. Epub 2017 Mar 8.
7
A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk.一种模拟人体使用的醋酸甲羟孕酮剂量及其对阴道感染猴-人免疫缺陷病毒风险的影响。
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):363-71. doi: 10.1097/QAI.0000000000000975.
8
Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.疫苗引发的黏膜和全身抗体反应与恒河猴幼猴体内猿猴免疫缺陷病毒血症的降低有关。
J Virol. 2016 Jul 27;90(16):7285-7302. doi: 10.1128/JVI.00481-16. Print 2016 Aug 15.
9
Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences.利用HIV-1循环重组型01_AE env序列制备黏膜可传播的SHIV攻击病毒储备液。
PLoS Pathog. 2016 Feb 5;12(2):e1005431. doi: 10.1371/journal.ppat.1005431. eCollection 2016 Feb.
10
Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.恩曲他滨与富马酸替诺福韦二吡呋酯联合用药可预防感染沙眼衣原体和阴道毛滴虫的猕猴发生阴道猿猴/人类免疫缺陷病毒感染。
J Infect Dis. 2016 May 15;213(10):1541-5. doi: 10.1093/infdis/jiw002. Epub 2016 Jan 6.

本文引用的文献

1
Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.非人灵长类动物在候选艾滋病疫苗评估中的作用:行业视角。
Curr Opin HIV AIDS. 2010 Sep;5(5):377-85. doi: 10.1097/COH.0b013e32833d2e19.
2
Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.恒河猴接种猴免疫缺陷病毒 SIVmac239Delta nef 后,可延迟在多次重复低剂量异源 SIV 挑战后获得感染和控制病毒复制。
J Virol. 2010 Sep;84(18):9190-9. doi: 10.1128/JVI.00041-10. Epub 2010 Jun 30.
3
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.摆弄HIV疫苗:利用恒河猴为临床试验确定“把关因素”
Nat Rev Immunol. 2009 Oct;9(10):717-28. doi: 10.1038/nri2636.
4
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.单独含替诺福韦或含替诺福韦与恩曲他滨的局部凝胶可使猕猴完全免受反复阴道感染猿猴-人类免疫缺陷病毒。
J Virol. 2009 Oct;83(20):10358-65. doi: 10.1128/JVI.01073-09. Epub 2009 Aug 5.
5
Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments.在重复低剂量攻击实验中检测HIV疫苗效果的效能。
J Infect Dis. 2009 Aug 15;200(4):609-13. doi: 10.1086/600891.
6
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.低滴度抗体对猕猴低剂量重复黏膜SHIV攻击具有有效的保护作用。
Nat Med. 2009 Aug;15(8):951-4. doi: 10.1038/nm.1974. Epub 2009 Jun 7.
7
Assessing vaccine effects in repeated low-dose challenge experiments.在重复低剂量攻击实验中评估疫苗效果。
Biometrics. 2009 Dec;65(4):1223-32. doi: 10.1111/j.1541-0420.2009.01189.x.
8
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies.每次性行为中异性感染HIV-1的风险:观察性研究的系统评价与荟萃分析
Lancet Infect Dis. 2009 Feb;9(2):118-29. doi: 10.1016/S1473-3099(09)70021-0.
9
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.通过每日或间歇性使用恩曲他滨和替诺福韦预防猕猴直肠感染猴-人免疫缺陷病毒。
PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.
10
Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.世界卫生组织/联合国艾滋病规划署/国际艾滋病疫苗倡议专家小组关于“IIB期疗效试验作为评估预防性HIV疫苗的新策略”的磋商会议执行摘要及建议,2006年1月31日至2月2日,美国纽约,国际艾滋病疫苗倡议组织
AIDS. 2007 Feb 19;21(4):539-46. doi: 10.1097/QAD.0b013e328011a0c9.